Where AI is already paying off in drug development - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Where AI is already paying off in drug development

Pharmaceutical leaders point to faster manufacturing, smarter antibody design, and deeper data analysis.

  • By

  • Doug Brunk

  • September 9, 2026

  • 5 min

Share

  • 1

    AI is reshaping pharmaceutical development by improving efficiency in manufacturing and drug candidate design.

  • 2

    Generative AI can make mistakes and cannot replace essential scientific expertise and clinical judgment.

  • 3

    AI tools have been used to create digital twins that accelerate the drying of active pharmaceutical ingredients.

  • 4

    Machine learning helped Pfizer analyze antibody viscosity, speeding up design and avoiding lengthy testing cycles.

  • 5

    Pharmaceutical companies will likely use a mix of in-house and external AI tools, requiring internal expertise for evaluation.

Original Source(s)

Where AI is already paying off in drug development

  • by Doug Brunk

  • September 9, 2026

Related Content

Serostatus May Modify RA Activity–CV Link

Combined rheumatoid factor and anticitrullinated protein antibody status appeared to modify the association between baseline rheumatoid arthritis disease activity and subsequent cardiovascular events in an international observational cohort.

Tenderness Tracks Ultrasound Findings

Joint tenderness showed broader associations with concurrent ultrasound abnormalities than patient-reported pain among anti-cyclic citrullinated peptide–positive patients without clinical arthritis.

Top 10 CDC Updates Physicians Should Know

Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.